Clinical trials have shown that circulating FGF23 was reduced by FC treatment, consistent with studies in a genetic mouse model of CKD, where FGF23 was lowered by high dose FC (Block et al., 2015, 2019; Francis et al., 2019). The gene discussed is FGF23; the disease is chronic kidney disease.